PROPOFOL
Subarachnoid Hemorrhage, Aneurysmal
Jenna L Leclerc MD, PhDSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Subarachnoid Hemorrhage, Aneurysmal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
S-Ketamine Rigshospitalet, Denmark | Phase 4 | BB |
(-)-OSU 6162 Oslo University Hospital | Phase 2 | B |
Erythropoietin Beta University of Cambridge | Phase 2 | B |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Jenna L Leclerc MD, PhD | Phase 2/3 | B |
XENON Turku University Hospital | Phase 2 | CCC |
Oxygen Turku University Hospital | Phase 2 | CCC |
AIR Turku University Hospital | Phase 2 | CCC |
Same molecule, other indications
PROPOFOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →